H.C. Wainwright analyst Andrew Fein views the safety profile of DBV Technologies' (DBVT) Viaskin safety profile as a competitive advantage. After surveying 100 allergists, the analyst notes that the doctors expected their treated peanut allergy patients to grow by approximately 59% from the current year to five years from now. A key takeaway was that allergists identified safety and efficacy as their top concerns in treating peanut allergy patients, Fein tells investors in a research note. He believes this highlights a fundamental distinction between DBV's Viaskin, which he says offers efficacy with a superior safety profile, and Aimmune's (AIMT) Palforzia, which he says offers high reported efficacy with greater allergic reaction risk. Fein continues to believe these priorities can indicate relevance for both drugs, while emphasizing safety. He reiterates a Buy rating on DBV Technologies with a $25 price target. The analyst this morning also imitated Aimmune with a Neutral rating.